AIM ImmunoTech
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
AIM ImmunoTech company logo. | |
Trade name | AIM |
|---|---|
Traded as | AMEX: AIM |
| Industry | Biopharmaceutical |
| Headquarters | Ocala, Florida , USA |
Key people | CEO Thomas K. Equels, J.D. COO Peter W. Rodino III, J.D. CFO Ellen Lintal |
| Products | Ampligen Alferon |
| Services | Cancer and immunotherapy research |
| Total assets | $ 64.584 million (2020) |
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.